Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Cancer Research

• Publication date

  1991-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 1873800
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Short-termcis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells

  2004cited by this paper
• DNA cross-linking following exposure to cis-platinum in primary and serially passaged cultured cells derived from two murine fibrosarcomas

  2004cited by this paper
• Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells

  2004cited by this paper
• Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells.

  1991cited by this paper
• Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.

  1990cited by this paper
• Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.

  1990cited by this paper
• Metallothionein gene expression and resistance to cisplatin in human ovarian cancer

  1990cited by this paper
• The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.

  1990cited by this paper
• Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.

  1990cited by this paper
• Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.

  1990cited by this paper
• Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.

  1990cited by this paper
• An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines.

  1990cited by this paper
• Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair.

  1990cited by this paper
• Determinants of Drug Response in a Cisplatin‐resistant Human Lung Cancer Cell Line

  1990cited by this paper
• A study of human small‐cell lung carcinoma (hsclc) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (cddp) resistance

  1990cited by this paper
• The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.

  1990cited by this paper
• Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II).

  1990cited by this paper
• Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.

  1990cited by this paper
• Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.

  1989cited by this paper
• Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines.

  1989cited by this paper
• Isolation, characterization, and expression in Escherichia coli of two murine Mu class glutathione S-transferase cDNAs homologous to the rat subunits 3 (Yb1) and 4 (Yb2).

  1989cited by this paper
• DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA.

  1989cited by this paper
• Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines.

  1989cited by this paper
• Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA.

  1989cited by this paper
• Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line.

  1989cited by this paper
• Mechanisms of resistance to cis-diamminedichloroplatinum (II) in a rat ovarian carcinoma cell line.

  1989cited by this paper
• Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia.

  1989cited by this paper
• Molecular basis of cisplatin resistance in human carcinomas: model systems and patients.

  1989cited by this paper
• Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells.

  1989cited by this paper
• Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines.

  1988cited by this paper
• Interaction of cis-diamminedichloroplatinum(II) with sensitive and resistant L1210 cell lines. Drug binding to nuclei and DNA.

  1988cited by this paper
• Overexpression of metallothionein confers resistance to anticancer drugs.

  1988cited by this paper
• Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

  1988cited by this paper
• Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts.

  1988cited by this paper
• cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.

  1988cited by this paper
• The Mechanism of Acquired Resistance to Cisplatin by a Human Ovarian Cancer Cell Line

  1988cited by this paper
• Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.

  1988cited by this paper
• Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

  1988cited by this paper
• cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

  1988cited by this paper
• Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion.

  1988cited by this paper
• Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.

  1988cited by this paper
• The isolation and characterization of cisplatin-resistant rat ovarian cancer cells.

  1988cited by this paper
• Establishment and characterization of cisplatin‐resistant sublines of human lung cancer cell lines

  1988cited by this paper
• Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.

  1988cited by this paper
• Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.

  1988cited by this paper
• Mechanisms of Resistance to Platinum Drugs

  1988cited by this paper
• Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.

  1987cited by this paper
• Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes.

  1987cited by this paper
• Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.

  1987cited by this paper
• Factors influencing the sensitivity of two human bladder carcinoma cell lines to cis-diamminedichloroplatinum(II).

  1987cited by this paper
• Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells.

  1987cited by this paper
• Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells.

  1987cited by this paper
• cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).

  1987cited by this paper
• Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient

  1987cited by this paper
• Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).

  1987cited by this paper
• Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

  1987cited by this paper
• Establishment and characterisation of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies

  1987cited by this paper
• Differential expression of collateral sensitivity or resistance to cisplatin in human bladder carcinoma cell lines pre‐exposed in vitro to either X‐irradiation or cisplatin

  1987cited by this paper
• Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).

  1986cited by this paper
• Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines.

  1986cited by this paper
• Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.

  1986cited by this paper
• Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.

  1986cited by this paper
• Metallothionein.

  1986cited by this paper
• Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug.

  1986cited by this paper
• Walker rat carcinoma cells are exceptionally sensitive to cis-diamminedichloroplatinum(II) (cisplatin) and other difunctional agents but not defective in the removal of platinum-DNA adducts.

  1986cited by this paper
• Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion.

  1986cited by this paper
• Establishment of a cisplatin-resistant human ovarian cancer cell line.

  1986cited by this paper
• Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.

  1986cited by this paper
• Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.

  1985cited by this paper
• Alkylating agent resistance: in vitro studies with human cell lines.

  1985cited by this paper
• Current therapy of ovarian carcinoma: an overview.

  1985cited by this paper
• Chemotherapy of ovarian cancer.

  1984cited by this paper
• The significance of DNA cross-linking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells.

  1982cited by this paper
• Assays for differentiation of glutathione S-transferases.

  1981cited by this paper
• DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard.

  1981cited by this paper
• Differential cytotoxicity and DNA cross-linking in normal and transformed human fibroblasts treated with cis-diamminedichloroplatinum(II).

  1981cited by this paper
• Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine.

  1980cited by this paper
• Chemotherapy of ovarian cancer.

  1978cited by this paper
• Growth of human tumour cell colonies from biopsies using two soft-agar techniques.

  1978cited by this paper
• Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

  1977cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein).

  1969cited by this paper
• Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.

  1967cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Synthesis and structure-activity relationships of tetrazolato-bridged dinuclear platinum(II) complexes: A small modification at tetrazole C5 markedly influences the in vivo antitumor efficacy.

  2019cites this paper
• DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine

  2016cites this paper
• Targeted Drug Discovery: Targeting a Specific Conformation of MutS/MSH Proteins with Small Molecules

  2010cites this paper
• The rational design of anticancer platinum complexes: the importance of the structure-activity relationship.

  2009cites this paper
• cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines

  2009cites this paper
• Changes in antioxidant defense status in response to cisplatin and 5-FU in esophageal carcinoma.

  2008cites this paper
• Synthesis, characterization and antiproliferative studies of the enantiomers of cis-[(1,2-camphordiamine)dichloro]platinum(II) complexes.

  2008cites this paper
• Multiple end‐point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: Implications for predictive testing

  2007cites this paper
• Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel‐induced cancer cell death both in vitro and in vivo

  2006cites this paper
• Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53.

  2006cites this paper
• 5-Fluorouracil but Collateral Sensitivity to Methotrexate Carcinoma Cell Line Expressing Cross-Resistance to Characterization of a Cisplatin-resistant Human Ovarian

  2006cites this paper
• Analysis of DNA damage and cellular responses to platinum-based chemotherapeutic agents in 'in vitro' models of non-small cell lung cancer

  2005cites this paper
• Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2–related protein Bad

  2005influential citation
• Antioxidative Mikronährstoffe als Zusatzstoffe in der Onkologie

  2004cites this paper
• Glutathione-related enzymes, glutathione and multidrug resistance

  2004cites this paper
• A Phase I and Pharmacodynamic Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed, Refractory, or High-Risk Acute Leukemia

  2004cites this paper
• Antioxidants in cancer therapy: Is there a rationale to recommend antioxidants during cancer therapy?

  2003cites this paper
• 1 2 Cisplatin

  2003cites this paper
• Codominance of cisplatin resistance in somatic cell hybrids

  2003cites this paper
• DNA‐adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy

  2000cites this paper
• Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer.

  2000cites this paper
• Diagnostics of multidrug resistance in cancer.

  1998cites this paper
• Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins.

  1998cites this paper
• Specific binding of human SRY (Sex-Determining Region Y) to DNA adducts of the anticancer drug cisplatin

  1997influential citation
• Response of sensitive and resistant IgM immunocytomas to cis-diamminedichloroplatinum(II) does not correlate with the platination level or with the formation or removal of DNA adducts

  1997cites this paper
• Effect of geometric isomerism in dinuclear platinum antitumour complexes on the rate of formation and structure of intrastrand adducts with oligonucleotides.

  1997cites this paper
• DNA Repair capacity and cisplatin sensitivity of human testis tumour cells

  1997cites this paper
• Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells.

  1996cites this paper
• DNA repair: enzymatic mechanisms and relevance to drug response.

  1996cites this paper
• In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin.

  1996cites this paper
• Host cell reactivation of cisplatin-treated adenovirus is reduced in nucleotide excision repair deficient mammalian cells and several human tumour cells.

  1996cites this paper
• DNA Repair and the Carrier Ligand Specificity of Platinum Resistance

  1996cites this paper
• Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II).

  1995cites this paper
• Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.

  1995cites this paper
• Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes.

  1995cites this paper
• The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review).

  1995cites this paper
• Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines.

  1994cites this paper
• Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel Trans platinum complex, JM335 [Trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)]

  1994cites this paper
• Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.

  1994cites this paper
• Differential formation, repair and tolerance of Cisplatin-induced DNA damage in two human small cell lung carcinoma cell lines

  1994cites this paper
• Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair.

  1994cites this paper
• Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies.

  1994cites this paper
• Mechanisms of acquired resistance to cisplatin.

  1994cites this paper
• Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia.

  1994cites this paper
• Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.

  1994cites this paper
• Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro.

  1994cites this paper
• Multiple mechanisms of resistance to cisplatin toxicity in an Escherichia coli K12 mutant.

  1994cites this paper
• Cellular pharmacodynamics of anticancer drugs.

  1993cites this paper
• Glutathione and glutathione linked enzymes in human small cell lung cancer cell lines.

  1993cites this paper
• Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.

  1993cites this paper
• Evidence of differential cisplatin‐DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines

  1993cites this paper
• Immunohistochemical study of glutathione‐related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity

  1993cites this paper
• Application of high-performance liquid chromatography for recognition of covalent nucleic acid modification with anticancer drugs.

  1993cites this paper
• Molecular Aspects of Platinum-DNA Interactions

  1993cites this paper
• New platinum antitumor complexes.

  1993cites this paper
• Ovarian cancer, Part I: Biology.

  1992cites this paper
• Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.

  1992cites this paper
• Multiple effects of 3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensitive and -resistant rat ovarian tumor cell lines.

  1992cites this paper
• Cisplatin resistance in human cancers.

  1991cites this paper